These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36893481)

  • 1. Ustekinumab Use in Pediatric Inflammatory Bowel Disease: A French Multicenter Study From the Pediatric GETAID.
    Koudsi M; Martinez-Vinson C; Pigneur B; Willot S; Djamal D; Enaud R; Rebeuh J; Dupont C; Dabadie A; Bertrand V; Hugot JP; Lachaux A; Ruemmele F; Viala J; Duclaux-Loras R; Pédiatrique G
    J Pediatr Gastroenterol Nutr; 2023 Jun; 76(6):763-770. PubMed ID: 36893481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
    Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
    BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
    Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.
    Dayan JR; Dolinger M; Benkov K; Dunkin D; Jossen J; Lai J; Phan BL; Pittman N; Dubinsky MC
    J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):61-67. PubMed ID: 31058718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
    Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
    Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.
    Olbjørn C; Rove JB; Jahnsen J
    Paediatr Drugs; 2020 Aug; 22(4):409-416. PubMed ID: 32378002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in Clinical Presentation of Eosinophilic Esophagitis in Pediatric Patients With Ulcerative Colitis and Crohn Disease.
    Splawski J; Aktay AN; Perry S; Baez-Socorro V; DeLozier S; Sferra TJ; Moses J
    J Pediatr Gastroenterol Nutr; 2022 Jul; 75(1):76-80. PubMed ID: 35442240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease.
    Potdar AA; Dube S; Naito T; Li K; Botwin G; Haritunians T; Li D; Casero D; Yang S; Bilsborough J; Perrigoue JG; Denson LA; Daly M; Targan SR; Fleshner P; Braun J; Kugathasan S; Stappenbeck TS; McGovern DPB
    Gastroenterology; 2021 Feb; 160(3):809-822.e7. PubMed ID: 33160965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab for skin reactions associated with anti-tumor necrosis factor-α agents in patients with inflammatory bowel diseases: A single-center retrospective study.
    Ezzedine K; Visseaux L; Cadiot G; Brixi H; Bernard P; Reguiai Z
    J Dermatol; 2019 Apr; 46(4):322-327. PubMed ID: 30816581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
    Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
    J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
    Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Barré A; Colombel JF; Ungaro R
    Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
    Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
    BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature.
    Berinstein EM; Sheehan JL; Jacob J; Steiner CA; Stidham RW; Shannon C; Bishu S; Levine J; Cohen-Mekelburg SA; Waljee AK; Higgins PDR; Berinstein JA
    Dig Dis Sci; 2023 Jun; 68(6):2604-2623. PubMed ID: 36807832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice.
    Ylisaukko-Oja T; Puttonen M; Jokelainen J; Koivusalo M; Tamminen K; Torvinen S; Voutilainen M
    Scand J Gastroenterol; 2022 Apr; 57(4):415-423. PubMed ID: 34927504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BIOLOGICAL THERAPY PENETRATION FOR INFLAMMATORY BOWEL DISEASE IN LATIN AMERICA: CURRENT STATUS AND FUTURE CHALLENGES.
    Quaresma AB; Coy CSR; Damião AOMC; Kaplan GG; Kotze PG
    Arq Gastroenterol; 2019; 56(3):318-322. PubMed ID: 31633732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn's disease: a retrospective chart review.
    Do P; Andersen J; Patel A; Semrin G; Sifuentes-Dominguez L; Luu P; Gurram B
    F1000Res; 2020; 9():316. PubMed ID: 34504690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.